The National Institute of Pharmaceutical Education and Research (NIPER, Kolkata) has been created as a centre of excellence for higher education, research and development in pharmaceutical sciences.
The Institute offers in M.S.(Pharm.) in Medicinal Chemistry, Natural Products and Pharmacoinformatics. The Institute admits students for the M.S(Pharm.) through a common entrance test conducted by NIPER, Mohali. In future the number of M.S. programs would be increased and Ph.D programs would also be started in various disciplines of pharmaceutical sciences every year.
Amgen and Merck known as MSD outside the United States and Canada, announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL). BLINCYTO is Amgen’s CD19 bispecific T cell engager (BiTE®), and KEYTRUDA is Merck’s anti-PD-1 antibody. The study is an open-label, multicenter, randomized trial to evaluate safety and efficacy in patients with DLBCL.